These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 7522954)

  • 21. CD16- CD56+ natural killer cells after bone marrow transplantation.
    Jacobs R; Stoll M; Stratmann G; Leo R; Link H; Schmidt RE
    Blood; 1992 Jun; 79(12):3239-44. PubMed ID: 1375847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential expression of the interleukin 2 receptor beta (p75) chain on human peripheral blood natural killer subsets.
    Nishikawa K; Saito S; Morii T; Kato Y; Narita N; Ichijo M; Ohashi Y; Takeshita T; Sugamura K
    Int Immunol; 1990; 2(6):481-6. PubMed ID: 1707657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.
    Levitt LJ; Nagler A; Lee F; Abrams J; Shatsky M; Thompson D
    J Clin Invest; 1991 Jul; 88(1):67-75. PubMed ID: 1676038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accumulation of CD16-CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua.
    Nishikawa K; Saito S; Morii T; Hamada K; Ako H; Narita N; Ichijo M; Kurahayashi M; Sugamura K
    Int Immunol; 1991 Aug; 3(8):743-50. PubMed ID: 1716974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of leukemic large granular lymphocytes by interleukin-2 via the p75 interleukin-2 receptor.
    Yoon HJ; Sugamura K; Loughran TP
    Leukemia; 1990 Dec; 4(12):848-50. PubMed ID: 2147047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-12 is involved in the activation of CD3+ granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes.
    Zambello R; Trentin L; Cassatella MA; Raimondi R; Cerutti A; Enthammer C; Facco M; Agostini C; Semenzato G
    Br J Haematol; 1996 Feb; 92(2):308-14. PubMed ID: 8602990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.
    Weil-Hillman G; Voss SD; Fisch P; Schell K; Hank JA; Sosman JA; Sugamura K; Sondel PM
    Cancer Res; 1990 May; 50(9):2683-91. PubMed ID: 1691679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation via the CD3 and CD16 pathway mediates interleukin-2-dependent autocrine proliferation of granular lymphocytes in patients with granular lymphocyte proliferative disorders.
    Hoshino S; Oshimi K; Teramura M; Mizoguchi H
    Blood; 1991 Dec; 78(12):3232-40. PubMed ID: 1835892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low doses of rIL2 after autologous bone marrow transplantation induce a "prolonged" immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas.
    Raspadori D; Lauria F; Ventura MA; Tazzari PL; Ferrini S; Miggiano MC; Rondelli D; Tura S
    Ann Hematol; 1995 Oct; 71(4):175-9. PubMed ID: 7578523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of LFA-1/ICAM-1 in interleukin-2-stimulated lymphocyte proliferation.
    Vyth-Dreese FA; Dellemijn TA; Frijhoff A; van Kooyk Y; Figdor CG
    Eur J Immunol; 1993 Dec; 23(12):3292-9. PubMed ID: 7903074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo activated cord blood lymphocytes express high affinity interleukin-2 receptor: evaluation of their responsiveness to in vitro stimulation with recombinant interleukin-2.
    Montagna D; Moretta A; Marconi M; Mingrat G; Gasparoni A; Giarola M; Maccario R
    Biol Neonate; 1992; 62(6):385-94. PubMed ID: 1472581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
    Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
    Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2.
    Moltó L; Carballido J; Manzano L; Martinez-Martin B; Esquivel F; Chafer J; Olivier C; Alvarez-Mon M
    J Immunother; 1999 May; 22(3):260-7. PubMed ID: 10335486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells.
    Fortis C; Ferrero E; Besana C; Biffi M; Heltai S; Galli L; Borri A; Schoenheit A; Rugarli C
    Cancer Immunol Immunother; 1990; 32(3):161-6. PubMed ID: 2289209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of recombinant human interleukin-2: biological features and clinical relevance.
    Hänninen EL; Knüver-Hopf J; Atzpodien J
    Biotherapy; 1993; 6(4):251-61. PubMed ID: 7517168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes.
    Zambello R; Facco M; Trentin L; Sancetta R; Tassinari C; Perin A; Milani A; Pizzolo G; Rodeghiero F; Agostini C; Meazza R; Ferrini S; Semenzato G
    Blood; 1997 Jan; 89(1):201-11. PubMed ID: 8978293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purified human T cells stimulated with cross-linked anti-CD3 monoclonal antibody OKT3: rIL-1 is a co-stimulatory factor for CD4+CD29+CD45RA- T cells.
    Panzer S; Geller RL; Bach FH
    Scand J Immunol; 1990 Oct; 32(4):359-71. PubMed ID: 1700468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects.
    De Laurenzi A; Iudicone P; Zoli V; De Rosa L; Guglielmetti M; Pescarollo A; Papetti C; Pacilli L; Lapponi P; Petti N
    J Hematother; 1995 Apr; 4(2):113-20. PubMed ID: 7633841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
    Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
    Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.